Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.73 |
| ▸ | DHODH | Q02127 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901619 | 0.89 | DHODH (0.90) | CYP2C9DHODHKMT2AALDH1A1MEN1 | |
| SCHEMBL6209856 | 0.88 | KDM4E (0.76) | DHODHKMT2AMEN1KDM4ELMNA | |
| SCHEMBL30604089 | 0.86 | KMT2A (0.73) | CYP2C9DHODHKMT2AALDH1A1MEN1 | |
| SCHEMBL17308320 | 0.86 | KMT2A (0.73) | CYP2C9DHODHKMT2AALDH1A1MEN1 | |
| SCHEMBL13312206 | 0.86 | DHODH (0.74) | CYP2C9DHODHKMT2AMEN1KDM4E | |
| SCHEMBL17348467 | 0.83 | KDM4E (0.62) | CYP2C9DHODHKMT2AMEN1KDM4E | |
| SCHEMBL7479593 | 0.82 | DHODH (0.81) | CYP2C9DHODHKMT2AALDH1A1MEN1 | |
| SCHEMBL13312211 | 0.80 | POLB (0.78) | DHODHKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL4854898 | 0.80 | DHODH (0.63) | CYP2C9DHODHKMT2AALDH1A1MEN1 | |
| SCHEMBL25775237 | 0.80 | KMT2A (0.65) | DHODHKMT2AALDH1A1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | CYP2C9 1717/4885DHODH 1867/4885KMT2A 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.